After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too? Thanks to Slack for supporting Motley Fool. Learn more at <a href="slack.com">slack.com.</a>

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too? Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being&nbsp;run by proven CEOs. Could experience turn&nbsp;Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too? Thanks to Slack for supporting Motley Fool. Learn more at <a href="slack.com" rel="noopener noreferrer">slack.com.</a> &nbsp;

Healthcare: 3 Been-There-Done-That Biotech CEOs That Are Doing it Again

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: 3 Been-There-Done-That Biotech CEOs That Are Doing it Again

Sign up to save your podcasts

Healthcare: 3 Been-There-Done-That Biotech CEOs That Are Doing it Again

Healthcare: 3 Been-There-Done-That Biotech CEOs That Are Doing it Again